{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:01:47Z","timestamp":1793325707454,"version":"4.5.0"},"reference-count":134,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1053\/j.ajkd.2015.02.340","type":"journal-article","created":{"date-parts":[[2015,5,3]],"date-time":"2015-05-03T02:27:34Z","timestamp":1430620054000},"page":"857-868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"title":["Thrombotic Microangiopathy, Cancer, and Cancer Drugs"],"prefix":"10.1053","volume":"66","author":[{"given":"Hassan","family":"Izzedine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2015.02.340_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00002018-200124070-00002","article-title":"Drug-induced thrombotic microangiopathy; incidence, prevention, and management","volume":"24","author":"Pisoni","year":"2001","journal-title":"Drug Saf"},{"key":"10.1053\/j.ajkd.2015.02.340_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/cc5064","article-title":"Bench-to-bedside review: thrombocytopenia-associated multiple organ failure: a newly appreciated syndrome in the critically ill","volume":"10","author":"Nguyen","year":"2006","journal-title":"Crit Care"},{"key":"10.1053\/j.ajkd.2015.02.340_bib3","first-page":"141","article-title":"Miscellaneous secondary thrombotic microangiopathy","volume":"24","author":"Kwaan","year":"1987","journal-title":"Semin Hematol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib4","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1002\/1097-0142(19811215)48:12<2583::AID-CNCR2820481208>3.0.CO;2-6","article-title":"Renal disease after mitomycin C therapy","volume":"48","author":"Hanna","year":"1981","journal-title":"Cancer"},{"key":"10.1053\/j.ajkd.2015.02.340_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ajh.2830210309","article-title":"Thrombotic thrombocytopenic purpura subsequent to acute myelogenous leukemia chemotherapy","volume":"21","author":"Byrnes","year":"1986","journal-title":"Am J Hematol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib6","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","article-title":"Cancer-associated hemolytic uremic syndrome: analysis of 85 cases from a national registry","volume":"7","author":"Lesesne","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Anti-VEGF associated kidney diseases: an 8-year monocentric observational study","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.ajkd.2015.02.340_bib8","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.1986.4.9.1405","article-title":"Vascular toxicity associated with antineoplastic agents","volume":"4","author":"Doll","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.2.4790.897","article-title":"Thrombotic microangiopathic haemolytic anemia","volume":"2","author":"Symmers","year":"1952","journal-title":"Br Med J"},{"key":"10.1053\/j.ajkd.2015.02.340_bib10","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 Published May 28, 2009 (v4.03: June 14, 2010). US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed November 3,\u00a02014."},{"key":"10.1053\/j.ajkd.2015.02.340_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"10.1053\/j.ajkd.2015.02.340_bib12","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.lpm.2011.10.028","article-title":"Genetics of hemolytic uremic syndromes","volume":"41","author":"Malina","year":"2012","journal-title":"Presse Med"},{"key":"10.1053\/j.ajkd.2015.02.340_bib13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1523-1755.1998.00824.x","article-title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome","volume":"53","author":"Warwicker","year":"1998","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2015.02.340_bib14","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1073\/pnas.2135497100","article-title":"Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome","volume":"100","author":"Richards","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.ajkd.2015.02.340_bib15","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/jmg.2004.019083","article-title":"Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome","volume":"41","author":"Fremeaux-Bacchi","year":"2004","journal-title":"J\u00a0Med Genet"},{"key":"10.1053\/j.ajkd.2015.02.340_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.2830330109","article-title":"Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C-related hemolytic-uremic syndrome","volume":"33","author":"Monteagudo","year":"1990","journal-title":"Am J Hematol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ajh.2830420306","article-title":"Abnormalities of von Willebrand factor multimers in drug-associated thrombotic microangiopathies","volume":"42","author":"Charba","year":"1993","journal-title":"Am J Hematol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.344","article-title":"Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy","volume":"85","author":"Izzedine","year":"2014","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2015.02.340_bib19","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2015.02.340_bib20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.1985.3.5.723","article-title":"Carcinoma-associated hemolytic\u2013uremic syndrome. A complication of mitomycin C chemotherapy","volume":"3","author":"Cantrell","year":"1985","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib21","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/1097-0142(19861001)58:7<1428::AID-CNCR2820580709>3.0.CO;2-J","article-title":"A\u00a0syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma","volume":"58","author":"Sheldon","year":"1986","journal-title":"Cancer"},{"key":"10.1053\/j.ajkd.2015.02.340_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.ajkd.2015.02.340_bib23","first-page":"161","article-title":"Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents","volume":"24","author":"Murgo","year":"1987","journal-title":"Semin Hematol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0046-8177(79)80049-0","article-title":"Chronic glomerular microangiopathy and metastatic carcinoma","volume":"10","author":"Laffay","year":"1979","journal-title":"Hum Pathol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1634\/theoncologist.8-4-375","article-title":"Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer","volume":"8","author":"Chang","year":"2003","journal-title":"Oncologist"},{"key":"10.1053\/j.ajkd.2015.02.340_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.12-1-11","article-title":"Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases","volume":"12","author":"Francis","year":"2007","journal-title":"Oncologist"},{"key":"10.1053\/j.ajkd.2015.02.340_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajh.20783","article-title":"Management of cancer-associated thrombotic microangiopathy: what is the right approach?","volume":"82","author":"Werner","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib28","first-page":"908","article-title":"Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia","volume":"25","author":"George","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"10.1053\/j.ajkd.2015.02.340_bib29","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1200\/JCO.2011.36.7433","article-title":"Thrombotic microangiopathy and disseminated intravascular coagulation associated with carcinocythemia in a patient with breast cancer","volume":"29","author":"Robier","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib30","first-page":"172","article-title":"Disseminated intravascular coagulation due to malignancy","volume":"17","author":"Colman","year":"1990","journal-title":"Semin Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12032-007-0048-2","article-title":"Breast cancer with an unusual leukemia-like presentation: case report and literature review","volume":"25","author":"Chang","year":"2008","journal-title":"Med Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib32","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S1470-2045(06)70730-6","article-title":"An acute-leukemia-like picture due to breast carcinoma cells","volume":"7","author":"Pitini","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2141.1970.tb01433.x","article-title":"Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma","volume":"18","author":"Brain","year":"1970","journal-title":"Br J Haematol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib34","first-page":"2244","article-title":"De\ufb01cient activity of von Willebrand\u2019s factor-cleaving protease in patients with disseminated malignancies","volume":"59","author":"Oleksowicz","year":"1999","journal-title":"Cancer Res"},{"key":"10.1053\/j.ajkd.2015.02.340_bib35","first-page":"454","article-title":"Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease)","volume":"88","author":"Mannucci","year":"2003","journal-title":"Haematologica"},{"key":"10.1053\/j.ajkd.2015.02.340_bib36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2141.2001.02704.x","article-title":"Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease","volume":"113","author":"Fontana","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib37","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2015.02.340_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.tp.0000297998.33418.7e","article-title":"Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study","volume":"85","author":"Siami","year":"2008","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2015.02.340_bib39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2215\/CJN.02070508","article-title":"Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis","volume":"4","author":"Changsirikulchai","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bmt.1701830","article-title":"Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation","volume":"24","author":"Iacopino","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.ajkd.2015.02.340_bib41","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.bmt.1702849","article-title":"Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes","volume":"27","author":"Roy","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.ajkd.2015.02.340_bib42","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma","volume":"44","author":"George","year":"2004","journal-title":"Transfusion"},{"key":"10.1053\/j.ajkd.2015.02.340_bib43","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/sj.ki.5000055","article-title":"Acute renal failure in hematopoietic cell transplantation","volume":"69","author":"Parikh","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2015.02.340_bib44","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/qjmed\/89.10.751","article-title":"Cyclosporin nephrotoxicity in heart and lung transplant patients","volume":"89","author":"Griffiths","year":"1996","journal-title":"QJM"},{"key":"10.1053\/j.ajkd.2015.02.340_bib45","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1038\/ki.2008.622","article-title":"The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007","volume":"112","author":"George","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2015.02.340_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5482\/HAMO-12-10-0016","article-title":"The Oklahoma Thrombotic Thrombocytopenic Purpura-Haemolytic Uraemic Syndrome Registry. A model for clinical research, education and patient care","volume":"33","author":"George","year":"2013","journal-title":"Hamostaseologie"},{"key":"10.1053\/j.ajkd.2015.02.340_bib47","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/sj.bjc.6690242","article-title":"Elevated reticulocyte count: a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report","volume":"79","author":"Serke","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1053\/j.ajkd.2015.02.340_bib48","first-page":"905","article-title":"Hemolyticuremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia","volume":"85","author":"Gasser","year":"1955","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1053\/j.ajkd.2015.02.340_bib49","first-page":"369","article-title":"Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature","volume":"6","author":"Saif","year":"2005","journal-title":"JOP"},{"key":"10.1053\/j.ajkd.2015.02.340_bib50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4065\/77.4.323","article-title":"Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects","volume":"77","author":"Raife","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.ajkd.2015.02.340_bib51","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1526-0968.2003.00127.x","article-title":"Drug-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: a concise review","volume":"8","author":"Dlott","year":"2004","journal-title":"Ther Apher Dial"},{"key":"10.1053\/j.ajkd.2015.02.340_bib52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ki.2013.408","article-title":"Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer","volume":"85","author":"Shavit","year":"2014","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2015.02.340_bib53","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1002\/1097-0142(19941201)74:11<3059::AID-CNCR2820741125>3.0.CO;2-Z","article-title":"Cisplatin\u2013associated hemolytic uremic syndrome","volume":"74","author":"Canoplat","year":"1994","journal-title":"Cancer"},{"key":"10.1053\/j.ajkd.2015.02.340_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/1097-0142(19850101)55:1<51::AID-CNCR2820550109>3.0.CO;2-D","article-title":"Renal failure and hemolytic anemia associated with mitomycin C. A case report","volume":"55","author":"Price","year":"1985","journal-title":"Cancer"},{"key":"10.1053\/j.ajkd.2015.02.340_bib55","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000168178","article-title":"Silent renal microangiography after mitomycin C therapy","volume":"10","author":"Poch","year":"1990","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib56","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0272-6386(97)90042-1","article-title":"Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy","volume":"29","author":"Groff","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2015.02.340_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-101-1-41","article-title":"Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy","volume":"101","author":"Jackson","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2015.02.340_bib58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/1097-0142(19850101)55:1<47::AID-CNCR2820550108>3.0.CO;2-#","article-title":"Renal complications of mitomycin C therapy with special reference to the total dose","volume":"55","author":"Valavaara","year":"1985","journal-title":"Cancer"},{"key":"10.1053\/j.ajkd.2015.02.340_bib59","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/ndt\/gfl565","article-title":"Thrombotic microangiopathy and anti-VEGF agents","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2015.02.340_bib60","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1053\/ajkd.2002.35758","article-title":"Gemcitabine-associated hemolytic-uremic syndrome","volume":"40","author":"Walter","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2015.02.340_bib61","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","article-title":"Gemcitabine associated thrombotic thrombocytopenic purpura","volume":"8","author":"Zupancic","year":"2007","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1053\/j.ajkd.2015.02.340_bib62","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0272-6386(99)70194-0","article-title":"Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine","volume":"33","author":"Flombaum","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2015.02.340_bib63","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution","volume":"71","author":"Glezerman","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib64","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.20290","article-title":"Gemcitabine associated thrombotic microangiopathy","volume":"100","author":"Humphreys","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.ajkd.2015.02.340_bib65","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2","article-title":"A\u00a0review of hemolytic uremic syndrome in patients treated with gemcitabine therapy","volume":"85","author":"Fung","year":"1999","journal-title":"Cancer"},{"key":"10.1053\/j.ajkd.2015.02.340_bib66","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20174","article-title":"Doxycycline, gastrointestinal bleeding, and thrombotic microangiopathy","volume":"77","author":"Izzedine","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib67","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000226049","article-title":"Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy","volume":"42","author":"Licciardello","year":"1985","journal-title":"Oncology"},{"key":"10.1053\/j.ajkd.2015.02.340_bib68","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00000441-199106000-00006","article-title":"Case report: cisplatin-induced hemolytic uremic syndrome","volume":"301","author":"Khansur","year":"1991","journal-title":"Am J Med Sci"},{"key":"10.1053\/j.ajkd.2015.02.340_bib69","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/08860228909066955","article-title":"Hemolytic uremic syndrome following cisplatin, bleomycin, and vincristine chemotherapy. A report of a case and a review of the literature","volume":"11","author":"Gardner","year":"1989","journal-title":"Ren Fail"},{"key":"10.1053\/j.ajkd.2015.02.340_bib70","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00402723","article-title":"Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin","volume":"110","author":"Van der Meer","year":"1985","journal-title":"Cancer Res Clin Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib71","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/1097-0142(19901101)66:9<1914::AID-CNCR2820660910>3.0.CO;2-G","article-title":"Chemotherapy-related hemolytic\u2013uremic syndrome after the treatment of head and neck cancer. A case report","volume":"66","author":"Gradishar","year":"1990","journal-title":"Cancer"},{"key":"10.1053\/j.ajkd.2015.02.340_bib72","doi-asserted-by":"crossref","first-page":"570","DOI":"10.4065\/74.6.570","article-title":"Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production","volume":"74","author":"Porta","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.ajkd.2015.02.340_bib73","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000055365","article-title":"Chemotherapy-related hemolytic\u2013uremic syndrome following treatment of a carcinoma of the nasopharynx","volume":"61","author":"Thurnher","year":"2001","journal-title":"Oncology"},{"key":"10.1053\/j.ajkd.2015.02.340_bib74","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/ajkd.1998.v32.pm9708619","article-title":"Successful treatment of cisplatin\u2013induced hemolytic uremic syndrome with therapeutic plasma exchange","volume":"32","author":"Palmisano","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2015.02.340_bib75","doi-asserted-by":"crossref","DOI":"10.1097\/00001813-200309000-00014","article-title":"Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic\u2013uremic syndrome due to gemcitabine","volume":"14","author":"Rabinowits","year":"2003","journal-title":"Anticancer Drugs"},{"key":"10.1053\/j.ajkd.2015.02.340_bib76","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/1097-0142(19890901)64:5<1017::AID-CNCR2820640508>3.0.CO;2-N","article-title":"Carboplatin-associated thrombotic microangiopathic hemolytic anemia","volume":"64","author":"Walker","year":"1989","journal-title":"Cancer"},{"key":"10.1053\/j.ajkd.2015.02.340_bib77","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00001813-199907000-00004","article-title":"Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine","volume":"10","author":"Gross","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1053\/j.ajkd.2015.02.340_bib78","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1200\/JCO.1996.14.5.1473","article-title":"Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer","volume":"14","author":"Rodenhuis","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib79","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12032-013-0568-x","article-title":"Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report","volume":"30","author":"Lams","year":"2013","journal-title":"Med Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib80","first-page":"61","article-title":"Oxaliplatin-mediated autoimmune thrombocytopenia","volume":"8","author":"Saif","year":"2009","journal-title":"Clin Colorectal Cancer"},{"key":"10.1053\/j.ajkd.2015.02.340_bib81","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-3-12","article-title":"Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature","volume":"3","author":"Bautista","year":"2010","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib82","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1200\/JCO.2012.42.5082","article-title":"Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review","volume":"30","author":"Niu","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib83","doi-asserted-by":"crossref","first-page":"31e","DOI":"10.1177\/030089161109700527","article-title":"Hemolytic uremic syndrome induced by infusion of oxaliplatin: a case report","volume":"97","author":"Racca","year":"2011","journal-title":"Tumori"},{"key":"10.1053\/j.ajkd.2015.02.340_bib84","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6904-6-5","article-title":"Hemolytic uremic syndrome following the infusion of oxaliplatin: case report","volume":"6","author":"Dahabreh","year":"2006","journal-title":"BMC Clin Pharmacol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib85","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib86","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1634\/theoncologist.2011-0422","article-title":"Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?","volume":"17","author":"Kwa","year":"2012","journal-title":"Oncologist"},{"key":"10.1053\/j.ajkd.2015.02.340_bib87","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-11-0804","article-title":"Thrombotic microangiopathy with targeted cancer agents","volume":"17","author":"Blake-Haskins","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.ajkd.2015.02.340_bib88","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1200\/JCO.2005.11.437","article-title":"Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies","volume":"23","author":"Kreitman","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib89","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2015.02.340_bib90","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2008.20.2630","article-title":"Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia","volume":"27","author":"Kreitman","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib91","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.888.888","article-title":"Phase I dose-escalation study of CAT-8015 (HA22), a CD22-specific targeted immunotoxin, in relapsed or refractory hairy cell leukemia","author":"Kreitman","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2015.02.340_bib92","first-page":"1302","article-title":"A\u00a0phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma","volume":"6","author":"Messmann","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.ajkd.2015.02.340_bib93","first-page":"3930","article-title":"Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers","volume":"53","author":"LeMaistre","year":"1993","journal-title":"Cancer Res"},{"key":"10.1053\/j.ajkd.2015.02.340_bib94","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V84.6.1765.1765","article-title":"Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study","volume":"84","author":"Foss","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2015.02.340_bib95","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3109\/10428190903186486","article-title":"A\u00a0phase I\/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia","volume":"50","author":"Lin","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"suppl 16S","key":"10.1053\/j.ajkd.2015.02.340_bib96","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1200\/jco.2005.23.16_suppl.6607","article-title":"Phase 1 study of combination rituximab with apolizumab in relapsed\/refractory B-cell lymphoma and chronic lymphocytic leukemia","volume":"23","author":"Dunleavy","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib97","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/rheumatology\/35.3.231","article-title":"CAMPATH-1H in rheumatoid arthritis\u2014an intravenous dose-ranging study","volume":"35","author":"Isaacs","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib98","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma","volume":"8","author":"Frangie","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib99","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/annonc\/mdm454","article-title":"Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome","volume":"18","author":"Kapiteijn","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib100","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Bollee","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2015.02.340_bib101","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1200\/JCO.2008.19.0108","article-title":"Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma","volume":"27","author":"Feldman","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib102","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1053\/j.ajkd.2004.12.017","article-title":"Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence?","volume":"45","author":"Al Aly","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2015.02.340_bib103","first-page":"267","article-title":"Kidney injury during VEGF inhibitor therapy","volume":"70","author":"den Deurwaarder","year":"2012","journal-title":"Neth J Med"},{"key":"10.1053\/j.ajkd.2015.02.340_bib104","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ndt\/gft465","article-title":"All anti-vascular endothelial growth factor drugs can induce \u2018pre-eclampsia-like syndrome': a RARe study","volume":"29","author":"Vigneau","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2015.02.340_bib105","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/annonc\/mdu390","article-title":"Phase I\/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors","volume":"25","author":"Soria","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib106","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4143\/crt.2008.40.4.211","article-title":"TTP-HUS associated with sunitinib","volume":"40","author":"Choi","year":"2008","journal-title":"Cancer Res Treat"},{"key":"10.1053\/j.ajkd.2015.02.340_bib107","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/MJT.0b013e3181eefe8b","article-title":"Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome","volume":"19","author":"Talebi","year":"2012","journal-title":"Am J Ther"},{"key":"10.1053\/j.ajkd.2015.02.340_bib108","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3816\/CGC.2008.n.019","article-title":"Sunitinib-induced acute hemolysis without hypertension: a case report","volume":"6","author":"Jain","year":"2008","journal-title":"Clin Genitourin Cancer"},{"key":"10.1053\/j.ajkd.2015.02.340_bib109","first-page":"271","article-title":"Cancer- and chemotherapy-associated thrombotic microangiopathy","volume":"Vol. 22","author":"Murgo","year":"1992"},{"key":"10.1053\/j.ajkd.2015.02.340_bib110","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/1097-0142(19930301)71:5<1882::AID-CNCR2820710527>3.0.CO;2-E","article-title":"Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome by protein A immunoadsorption of plasma","volume":"71","author":"Snyder","year":"1993","journal-title":"Cancer"},{"key":"10.1053\/j.ajkd.2015.02.340_bib111","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s12032-009-9333-6","article-title":"Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report","volume":"27","author":"Siau","year":"2010","journal-title":"Med Oncol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib112","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","author":"Nurnberger","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2015.02.340_bib113","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2015.02.340_bib114","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.transci.2010.09.018","article-title":"Efficacy and safety of rituximab in adult patients with idiopathic relapsing or\u00a0refractory thrombotic thrombocytopenic purpura: results of a\u00a0Spanish multicenter study","volume":"43","author":"de la Rubia","year":"2010","journal-title":"Transfus Apher Sci"},{"key":"10.1053\/j.ajkd.2015.02.340_bib115","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7326\/0003-4819-140-4-200402170-00028","article-title":"Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide","volume":"140","author":"Fakhouri","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2015.02.340_bib116","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2004-12-4885","article-title":"Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report","volume":"106","author":"Galbusera","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2015.02.340_bib117","first-page":"144","article-title":"Refractory thrombotic thrombocytopenic purpura successfully treated with a combination of rituximab and vincristine","volume":"48","author":"Kaneko","year":"2007","journal-title":"Rinsho Ketsueki"},{"key":"10.1053\/j.ajkd.2015.02.340_bib118","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","article-title":"Efficiency of\u00a0curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases","volume":"106","author":"Fakhouri","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2015.02.340_bib119","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1399-0012.2005.00334.x","article-title":"Anti-CD20 monoclonal antibody (rituximab) for life-threatening hemolytic-uremic syndrome","volume":"19","author":"Yassa","year":"2005","journal-title":"Clin Transpl"},{"key":"10.1053\/j.ajkd.2015.02.340_bib120","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.bmt.1705657","article-title":"Life-threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant recipient","volume":"39","author":"OstronoV","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.ajkd.2015.02.340_bib121","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1537-2995.2007.01266.x","article-title":"Protein A immunoadsorption therapy for refractory, mitomycin C-associated thrombotic microangiopathy","volume":"47","author":"Kasper","year":"2007","journal-title":"Transfusion"},{"key":"10.1053\/j.ajkd.2015.02.340_bib122","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00280-008-0900-x","article-title":"Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report","volume":"64","author":"Bharthuar","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib123","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jvir.2008.10.025","article-title":"Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab","volume":"20","author":"Onitilo","year":"2009","journal-title":"Vasc Interv Radiol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib124","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11255-013-0401-7","article-title":"Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis","volume":"46","author":"Orvain","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib125","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/DDDT.S42138","article-title":"Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis","volume":"7","author":"Mahe","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1053\/j.ajkd.2015.02.340_bib126","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.12686","article-title":"Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy","volume":"164","author":"Starck","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1053\/j.ajkd.2015.02.340_bib127","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.ajkd.2015.02.340_bib128","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2015.02.340_bib129","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2015.02.340_bib130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","article-title":"Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: result of a phase III, randomized, double-blind clinical trial","volume":"5","author":"Saito","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1053\/j.ajkd.2015.02.340_bib131","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/bmt.2009.242","article-title":"Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin","volume":"45","author":"Sakai","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.ajkd.2015.02.340_bib132","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.1016\/j.thromres.2010.06.024","article-title":"Successful treatment of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with recombinant human soluble thrombomodulin","volume":"126","author":"Sakai","year":"2010","journal-title":"Thromb Res"},{"key":"10.1053\/j.ajkd.2015.02.340_bib133","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2169\/internalmedicine.52.9180","article-title":"Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin","volume":"52","author":"Nishijima","year":"2013","journal-title":"Intern Med"},{"key":"10.1053\/j.ajkd.2015.02.340_bib134","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00281-011-0282-8","article-title":"Thrombomodulin and its role in inflammation","volume":"34","author":"Conway","year":"2012","journal-title":"Semin Immunopathol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615005430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615005430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:40:17Z","timestamp":1759459217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638615005430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":134,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0272638615005430"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.02.340","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic Microangiopathy, Cancer, and Cancer Drugs","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.02.340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}